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Summary Accumulating evidence suggests that the p53gene is a good target for molecular epidemiological studies. We previously reported
an association between the presence of p53 mutations and lifetime cigarette consumption. Although over 675 p53 mutations have been
reported in lung cancers in the literature thus far, very little is known about the nature of such changes in lung cancers in the absence of a
smoking background. In the present study, we therefore analysed 69 non-small-cell lung cancer specimens from individuals without any
history of active smoking and identified p53 mutations in 26% of the cases. Statistical analysis of the present cohort of non-smokers also
showed absence of significant relationship between p53mutations and age, sex, histological type or disease stage. Comparison of mutational
spectra between the present results in non-smokers and previously reported mutations in smokers clearly demonstrated G:C to T:A
transversions to be significantly less frequent in non-smokers than in smokers (OR 5.35, 95% Cl 1.77-16.12). Interestingly, G:C to C:G and
G:C to A:T mutations were also observed in tumours of non-smokers at similar frequencies to G:C to T:A mutations, suggesting that these
mutations can occur relatively frequently in the absence of active smoking. This study is, to our knowledge, the largest so faranalysing a well-
defined cohort of non-smokers in a single laboratory.
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The p53 gene is mutated in a large proportion of most human
cancers, including those developing in the lung, with over 6000
examples ofp53 mutations reported so far (Hainaut et al, 1997).
Accumulating evidence suggests that the frequency and spectrum
of p53 mutations may represent fingerprints left by specific
carcinogens and that the p53 gene is a good target for molecular
epidemiological studies aimed at determining risk factors for
neoplasia (Hollstein et al, 1991; Greenblatt et al, 1994).
Mutations in thep53 gene appear to be the most frequent molec-
ular change thus far identified in lung cancer (Naylor et al, 1987;
Rodenhuis et al, 1987; Harbour et al, 1988; Takahashi et al, 1989,
1991; Chiba et al, 1990; D'Amico et al, 1992; Hibi et al, 1992;
Miller et al, 1992; Suzuki et al, 1992, 1994; Washimi et al, 1995;
Kondo et al, 1996; Nagatake et al, 1996a and b). We previously
reported that p53 mutations occur in all histological subtypes of
human lung cancer, with frequencies of -75% in small-cell lung
cancer (SCLC) and -50% in non-small-cell lung cancer (NSCLC),
and that wild-typep53 can function as a potent in vitro and in vivo
growth suppressor in such lesions (Takahashi et al, 1989, 1991,
1992; Suzuki et al, 1992). Previous mutational analyses ofthep53
gene have shown that the most prevalent p53 mutation in lung
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cancers is the G:C toT:Atransversion, which is uncommon in other
cancers, such as colon carcinomas (Chiba et al, 1990; Takahashi et
al, 1991; D'Amico et al, 1992; Miller et al, 1992; Mitsudomi et al,
1992; Suzuki et al, 1992; Takeshima et al, 1993). Numerous
conventional epidemiological studies have provided evidence for a
strong association between lung cancer and cigarette smoking
(Muler, 1939; Doll and Hill, 1950; Levin et al, 1950; Wynder et al,
1950; US Public Health Service, 1964; US Department of Health
and Human Services, 1989; Shopland et al, 1991), and we have
previously shown that the presence ofp53 mutations is also closely
linked with lifetime cigarette consumption (Suzuki et al, 1992).
To date, over675 mutations in lung cancers have been deposited
in the database ofp53 somatic mutations in human tumours and
cell lines (Hainaut et al, 1997), but only eight instances could be
retrieved as those identified in individuals without a smoking
history (released January 1997). As smoking is presumably a
major determinant regarding the nature of genetic changes occur-
ring in lung neoplasia, we conducted the present study to identify
characteristics ofp53 mutations in lung cancers without this strong
influence by examining 69 NSCLC specimens from individuals
without any history ofsmoking. A comparison with the mutational
spectrum in smokers was included.
MATERIALS AND METHODS
Tumours
Sixty-nine NSCLC samples from patients without a past history of
active smoking were obtained at the time of surgery at either Aichi
1568p53 mutations in lung cancers ofnon-smokers 1569
Table 1 p53 mutations in lung cancers occurring in non-smoking individuals
Case Age (years) Sex Histologya Stage Codon Base change
L389 71 F AD IV 135 TGC to TAC
L122b 56 F AD 136 CAA to GAA
L265b 67 F ADSQ 136 CAA to GAA
L335 55 M AD IV 158 CGC to CTC
L292b 63 F AD III 166 TCA to TGA
L227b 71 F AD III 179 CAT to GAT
L125b 43 F AD III 179 QAT to GAT
L230 39 M AD III 194 CTT to CGT
L489 72 M SQ III 211 TTT to CTT
LlOb 42 F ADSQ 238 TGT to GGT
L416 42 F AD II 242 TGC to TAC
L504 61 F AD II 249 AGG to AGT
L428 68 M AD 249 AGG to AGT
L480 70 M AD 249 AGG to AGT
L215C 61 F AD 250 CCC to TTC
L244 74 F SQ 272 GTG to GTA
L424 58 F AD II 282 CGG to TGG
L184b 74 F AD int 4 ag to aa
aHistological subtype: AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adenosquamous carcinoma. bPreviously reported by Takagi et al (1995).
cPreviously reported by Suzuki et al (1992).
Table 2 Relationships between clinical characteristics and p53 mutations in lung cancers occurring in non-smoking individuals
Odds ratio (95% Cl)
Clinical feature No. of cases No. positive (%) Univariate Multivariate
Age (years)
<62 35 9 (25.7)
.62 34 9 (26.5) 1.30 (0.44-3.83) 1.13 (0.35-3.64)
Sex
Male 11 5 (45.4)
Female 58 13 (22.4) 2.42 (0.65-8.90) 2.26 (0.57-9.03)
Histology
Adenocarcinoma 61 14 (22.9)
Squamous cell carcinoma 6 2 (33.3)
Adenosquamous carcinoma 2 2 (100) 1.47 (0.25-8.79)a 1.00 (0.14-7.25)a
Tumour size
pTl 22 8 (36.3)
pT2 40 9 (22.5)
pT3 4 1 (25.0)
pT4 3 0 (0) 1.90 (0.79-4.57) NIb
Nodal involvement
pNO 40 9 (22.5)
pNl 13 5 (38.5)
pN2 16 4 (25.0) 0.87 (0.46-1.65) Nib
Disease stage
35 8 (22.9)
11 9 3 (33.3)
IIIA/IIIB 21 5 (23.8)
IV 4 2 (50.0) 1.16 (0.69-1.95)c 1.13 (0.66-1.92)c
aHistology was dischotomized for analysis (squamous cell carcinoma vs other histological types). bNl, not included. cFor an increase of one disease stage.
Cancer Center Hospital or National Chubu Hospital in Aichi
prefecture, Japan, and stored at -80°C until analysis at Aichi
Cancer Center Research Institute. The lung tumours were histo-
logically typed according to the World Health Organization's
histological classification. Mutations in some of the cases have
been reported in our previous studies (Suzuki et al, 1992; Takagi
et al, 1995).
Analysis of p53 mutations
Polymerase chain reaction (PCR)-single-strand conformation
polymorphism (SSCP) analysis was performed to detect p53
mutations in the region between exons 5 and 8 using genomic
DNA. The primer pairs used in this study were as follows: eSs,
5'-AGCAAGCTTGACTTTCAACTCTGTCTCCTT and eSas,
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5'-AGCGGATCCACCAGCCCTGTCGTCTCTCCA for exon 5;
e6s, 5'-AGCAAGCTTAGGCCTCTGATTCCTCACTGA and
e6as, 5'-AGCGGATCCCCAGAGACCCCAGTTGCAAAC for
exon 6; e7s, 5'-AGCAAGCTTAAGGCGCACTGGCTTCATCTT
and e7as, 5'-AGCGGATCCGCACAGCAGGCCAGTGTGCAG
for exon 7; and e8s, 5'-AGCAAGCTTAGGACCTGATTTCC-
TTACTGC and e8as, 5'-AGCGGATCCTGCACCCTTGGTCTC-
CTCCAC for exon 8. For exons 5, 7 and 8, the PCR products
labelled with [32P]dCTP were electrophoretically separated by 6%
non-denaturing polyacrylamide gel at 40 W for 3.5 h at SoC with
no cooling fan, while electrophoresis ofthe PCR products ofexon
6 was performed at 30 W for 4.5 h at SoC with a cooling fan. The
PCR conditions used to amplify genomic DNA were identical to
those detailed in our previous report (Horio et al, 1993). Genomic
DNAs demonstrating an altered mobility shift in this PCR-SSCP
analysis were further analysed by sequencing, and the identified
mutations confirmed by separate PCR and subsequent sequence
analysis as described previously (Horio et al, 1994).
Statistical analysis
Univariate and multivariate regression analyses were performed
using SAS/Windows Ver. 6.11 statistical software (SAS Institute,
Cary, NC, USA) to examine the possible relation of the presence
ofp53 mutations to various clinical characteristics, including age,
sex, histology and disease stage. Relative risks and 95% confi-
dence intervals for the dependent parameter were estimated condi-
tionally on the determinants (age, sex, histology and disease
stage). In addition, logistic regression analysis was also conducted
to examine the possible relation of the p53 mutational spectra to
lifetime cigarette consumption.
RESULTS
Detection of p53 mutations in lifetime never-smokers
PCR-SSCP and sequencing analyses identified mutations in exons
5-8 ofthep53 gene to be present in 18 (26%) of69 non-small-cell
lung cancer specimens from patients without any past history of
active smoking (Tables 1 and 2). Among the 18 p53 mutations
identified here, 17 were single nucleotide substitutions and the
remaining one was a CC:GG to TT:AA tandem double mutation
Table 3 Spectrum of p53 mutations in lung cancers occurring in non-
smoking individuals
Non-smokers (%) Smokersa (%) Odds ratio
Mutation (n = 18) (n = 50) (95% Cl)
G:C to A:T 27.7 22.0 1.41 (0.46-4.31)
G:C to T:A 22.2 48.0 5.35 (1.77-16.12)
G:C to C:G 27.7 10.0 0.67 (0.19-2.39)
A:T to G:C 5.5 2.0 0.68 (0.04-11.11)
A:T to C:G 11.1 4.0 0.68 (0.09-4.93)
A:T to T:A 0 2.0 NAb
Deletion 0 12.0 NA
CC:GG to TT:AA 5.5 0 NA
aCompilation of p53 mutations in smokers previously identified at the Aichi
Cancer Center (Suzuki et al, 1992; Takagi et al, 1995; YT, HO, TT and TT,
unpublished observation) and Hammon Center (Chiba et al, 1990; Mitsudomi
et al, 1992). bNA, not available because of inability to attain convergence
within 25 interations.
(Table 3). G:C to A:T transitions were observed in five (28%)
cases, four being found at non-CpG sites. G:C to C:G and G:C to
T:A transversions were observed in 28% and 22%, respectively, of
the cohort.
Relationship between p53 mutations and clinical
characteristics in lifetime never-smokers
Adenocarcinomas, known to be the least related to smoking among
the histological subtypes oflung cancers (Hanai et al, 1988), consti-
tuted the majority (61 of69) ofthe studied cohort, and 14 (23%) of
these had p53 mutations (Table 2). Although p53 mutations were
found more frequently in squamous cell carcinomas (33.3% vs
23%), the difference was not statistically significant.
Statistically significant differences were not apparent with strat-
ification according to age, gender, tumour size, nodal involvement,
distant metastasis or disease stage. Multivariate analysis using a
logistic regression model also showed absence of correlation
between the presence ofp53 mutations and clinical characteristics
including age, gender, histology and disease stage.
Comparison of p53 mutational spectrum between
lifetime never-smokers and individuals with smoking
histories
We next investigated whether there are any distinctions between
p53 mutations in lung cancers occurring in individuals with and
without smoking histories (Table 3). Although the database ofp53
somatic mutations in human tumours and cell lines available for
conducting molecular epidemiological analyses is exceedingly
large (Hollstein et al, 1991; Greenblatt et al, 1994; Hainaut et al,
1997), data on smoking histories are only limited. We therefore
compiled data for p53 mutations occurring in NSCLCs of
smokers, which were previously identified in the laboratories of
Aichi Cancer Center and Hammon Center, yielding 68 p53 muta-
tions within the region corresponding to that investigated here
(exons 5-8) (Chiba et al, 1990; Mitsudomi et al, 1992; Suzuki et
al, 1992; Takagi et al, 1995; YT, HO, TT and 1T, unpublished
observation). Comparison of the mutation spectra revealed that
G:C to T:A transversions, the most prevalent type of p53 muta-
tions in lung cancers of smokers, to be significantly less frequent
in their counterparts in non-smokers (OR 5.35, 95% CI
1.77-16.12) (Table 3). We noted that G:C to C:G transversions
occurred three times as frequently in non-smokers (28%) as in
smokers (10%); the difference was not statistically significant. No
other statistically significant differences were observed between
never-smokers and smokers, including G:C to A:T transitions.
DISCUSSION
The present study, conducted to assess the mutational characteris-
tics ofp53 in lung cancers in the absence ofthe major influence of
smoking, provides to our knowledge the only available data for a
reasonably large cohort of lung cancers occurring in individuals
without a past history of active smoking. p53 mutations were
detected in 26% of the NSCLC specimens examined, this rela-
tively low frequency for non-smokers being consistent with our
previous observation of a positive association between the pres-
ence ofp53 mutations and lifetime cigarette consumption (Suzuki
et al, 1992). Statistical analysis of the present cohort of non-
smokers also showed absence of significant relationship between
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p53 mutations and age, sex, histological type or disease stage.
Comparison of the mutation spectra between non-smokers and
smokers revealed a significant difference regarding the frequen-
cies of G:C to T:A transversions (OR 5.35, 95% CI 1.77-16.12).
While a number of previous studies, in which most of the speci-
mens were presumably from smokers, demonstrated G:C to T:A
transversions as the most prevalent and characteristic type of
mutations in lung cancers (Chiba et al, 1990; Takahashi et al,
1991; D'Amico et al, 1992; Miller et al, 1992; Mitsudomi et al,
1992; Suzuki et al, 1992; Takeshima et al, 1993), the present study
clearly indicates that this type ofmutation occurs significantly less
frequently without the influence of smoking. In fact, G:C to A:T
transitions and G:C to C:G transversions were found at similar
frequencies.
In contrast to our results, Takeshima et al (1993) previously
reported a predominance ofG:C to A:T transitions in lung cancers
of non-smoking atomic bomb survivors, identifying four muta-
tions each in the analysis of nine non-smoking atomic bomb
survivors and eight non-smoking control cases. It is notable that
the mutation frequency (47%) reported by Takeshima et al (1993)
is almost twice as high as that (26%) observed in the present study.
The discrepancy could be due to an unintended bias in their
analysis because ofthe inclusion ofp53 mutations in atomic bomb
survivors and the compilation ofthe data from other laboratories.
In addition to the significantly lower frequency of G:C to T:A
transversions, the CC:GG to TT:AA tandem double mutation iden-
tified may also provide an insight into one possible genesis oflung
cancers in non-smoking individuals. Loeb and co-workers have
clearly shown that while this tandem double mutation, a hallmark
of damage to DNA by UV irradiation, is not produced by DNA
polymerases or viral reverse transcriptases or by exposure to
chemical carcinogens, it can be caused by oxidative damage to
DNA (Reid and Loeb, 1993; Tkeshelashvili et al, 1993). G:C to
C:G and G:C to T:A transversions, which were also found to be
present at relatively high frequencies in the lung cancers of our
non-smoker cohort, are also known to be induced by reactive
oxygen species in certain circumstances (Moriya et al, 1991;
McBride, 1992). The present findings suggest that oxygen radical
species, which can be generated by various mechanisms, including
normal cellular processes (Fridovich, 1983), might have a role in
the development of lung cancers. Further studies are obviously
required to elucidate any relationship between DNA damage due
to reactive oxygen species and the pathogenesis oflung cancers.
It should be noted, however, that a number of other possibilities
must be considered, such as passive smoking and exposure to
environmental pollutants. In this regard, it is interesting that G:C
to T:A transversions were present in three (75%) of the four male
patients carrying p53 mutations in contrast to only one (7%) in 14
female patients, the difference being significant (P = 0.019 by
Fisher's exact probability test). The present finding is of interest
when we consider the fact that smoking at the work place is still
common in Japan, while until recently most women had usually
spent most of their lives at home as housewives. Accordingly, one
could speculate that these male patients may have been high-
exposure passive smokers for many years (Matsukura et al, 1984).
A number of conventional epidemiological studies have shown
that among the four major histological subtypes oflung cancers, the
adenocarcinoma is the least related to smoking, yet its incidence is
steadily increasing in various countries, including Japani and USA
(Watanabe et al, 1987; Travis et al, 1994). Future carefully
designed molecular epidemiological studies, with larger cohorts,
are required to identify risk factors and provide a basis for better
strategies of lung cancer prevention in non-smoking individuals.
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